Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant

Xing-Yu Cao, Jian-Ping Zhang, Yan-Li Zhao, Min Xiong, Jia-Rui Zhou, Yue Lu, Rui-Juan Sun, Zhi-Jie Wei, De-Yan Liu, Xian Zhang, Jun-Fang Yang, Peihua Lu, Xing-Yu Cao, Jian-Ping Zhang, Yan-Li Zhao, Min Xiong, Jia-Rui Zhou, Yue Lu, Rui-Juan Sun, Zhi-Jie Wei, De-Yan Liu, Xian Zhang, Jun-Fang Yang, Peihua Lu

Abstract

Background: Chimeric antigen receptor (CAR) T-cell therapy has demonstrated high initial complete remission (CR) rates in B-cell acute lymphoblastic leukemia (B-ALL) patients, including those who relapsed after transplant. However, the duration of remission requires improvements. Whether bridging to a second allogeneic hematopoietic stem cell transplant (allo-HSCT) after CAR-T therapy can improve long-term survival remains controversial. We retrospectively analyzed long-term follow-up data of B-ALL patients who relapsed post-transplant and received CAR-T therapy followed by consolidation second allo-HSCT to investigate whether such a treatment sequence could improve long-term survival.

Methods: A single-center, retrospective study was performed between October 2017 and March 2022, involving 95 patients who received a consolidation second transplant after achieving CR from CAR-T therapy.

Results: The median age of patients was 22.8 years (range: 3.3-52.8) at the second transplant. After the first transplant, 71 patients (74.7%) experienced bone marrow relapse, 16 patients (16.8%) had extramedullary relapse, 5 patients (5.3%) had both bone marrow and extramedullary relapse and 3/95 patients (3.2%) had positive minimal residual disease (MRD) only. Patients received autologous (n=57, 60.0%) or allogeneic (n=28, 29.5%) CAR-T cells, while 10 patients (10.5%) were unknown. All patients achieved CR after CAR-T therapy. Before second HSCT, 86 patients (90.5%) were MRD-negative, and 9 (9.5%) were MRD-positive. All second transplant donors were different from the first transplant donors. The median follow-up time was 623 days (range: 33-1901) after the second HSCT. The 3-year overall survival (OS) and leukemia-free survival (LFS) were 55.3% (95%CI, 44.3-66.1%) and 49.8% (95%CI, 38.7-60.9%), respectively. The 3-year relapse incidence (RI) and non-relapse mortality (NRM) were 10.5% (95%CI, 5.6-19.6%) and 43.6% (95%CI, 33.9-56.2%), respectively. In multivariate analysis, the interval from CAR-T to second HSCT ≤90 days was associated with superior LFS(HR, 4.10, 95%CI,1.64-10.24; p=0.003) and OS(HR, 2.67, 95%CI, 1.24-5.74, p=0.012), as well as reduced NRM (HR, 2.45, 95%CI, 1.14-5.24, p=0.021).

Conclusions: Our study indicated that CAR-T therapy followed by consolidation second transplant could significantly improve long-term survival in B-ALL patients who relapsed post-transplant. The second transplant should be considered in suitable patients and is recommended to be performed within 90 days after CAR-T treatment.

Keywords: B-ALL; CAR-T; LFS; NRM; relapse; second transplant.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2023 Cao, Zhang, Zhao, Xiong, Zhou, Lu, Sun, Wei, Liu, Zhang, Yang and Lu.

Figures

Figure 1
Figure 1
Cumulative incidence of aGVHD and cGVHD. (A) Cumulative incidence of grade 2-4 and grade 3-4 acute graft-versus-host disease (aGVHD) in 95 patients. The 100-day incidence of grade 2 to 4 aGVHD was 43.2% (95%CI, 34.3%-54.4%) and the incidence of grade 3 to 4 aGVHD was 8.4% (95%CI, 4.3%-16.3%). (B) Cumulative incidence of chronic graft-versus-host disease (cGVHD) in 95 patients. The incidence of any grade cGVHD at 180 days and at 2-year was 29.8% (95%CI, 21.8%-40.6%) and 44.2% (95CI, 35.1%-55.6%). The 180-day and 2-year cumulative incidence of extensive cGVHD was 24.5% (95%CI, 17.2%-34.9%) and 33.1% (95%CI, 24.9%-44.2%), respectively.
Figure 2
Figure 2
Long-term survival, including OS, LFS, RI and NRM. (A) Overall survival (OS) and leukemia-free survival (LFS) in 95 patients. After the second transplant, the 1-year OS and LFS were 69.3% (95%CI, 59.7%-78.2%) and 63.9% (95%CI, 54.0%-73.3%) respectively. The 3-year OS and LFS were 55.3% (95%CI, 44.3%-66.1%) and 49.8% (95%CI, 38.7%-60.9%), respectively. (B) Relapse incidence (RI) and non-relapse mortality (NRM) in 95 patients. The 3-year RI was 10.5% (95%CI, 5.6%-19.6%). The 3-year NRM was 43.6% (95%CI, 33.9%-56.2%).

References

    1. Nagler A, Labopin M, Houhou M, Aljurf M, Mousavi A, Hamladji RM, et al. . Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia:a study from the acute leukemia working party of the European society for blood and marrow transplantation. J Hematol Oncol (2021) 14:53. doi: 10.1186/s13045-021-01065-7
    1. Pavlu J, Labopin M, Niittyvuopio R, Socie G, Yakoub-Agha I, Wu D, et al. . Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia:a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. J Hematol Oncol (2019) 12:108. doi: 10.1186/s13045-019-0790-x
    1. Spyridonidis A, Labopin M, Schmid C, Volin L, Yakoub-Agha I, Stadler M, et al. . Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. an analysis on behalf of the acute leukemia working party of EBMT. Leukemia (2012) 26:1211–17. doi: 10.1038/leu.2011.351
    1. Collins RJ, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W, et al. . Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant (2000) 26:511–16. doi: 10.1038/sj.bmt.1702555
    1. Stein AS, Kantarjian H, Gokbuget N, Bargou R, Litzow MR, Rambaldi A, et al. . Blinatumomab for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2019) 25:1498–504. doi: 10.1016/j.bbmt.2019.04.010
    1. Papayannidis C, Sartor C, Dominietto A, Zappone E, Arpinati M, Marconi G, et al. . Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant. Hematol Oncol (2021) 39:580–83. doi: 10.1002/hon.2886
    1. Aldoss I, Otoukesh S, Zhang J, Mokhtari S, Ngo D, Mojtahedzadeh M, et al. . Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. Cancer (2022) 128:529–35. doi: 10.1002/cncr.33967
    1. Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. . Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med (2016) 375:740–53. doi: 10.1056/NEJMoa1509277
    1. Sadelain M, Riviere I, Riddell S. Therapeutic T cell engineering. Nature (2017) 545:423–31. doi: 10.1038/nature22395
    1. Graham C, Jozwik A, Pepper A, Benjamin R. Allogeneic CAR-T cells: more than ease of access? Cells (2018) 7:155. doi: 10.3390/cells7100155
    1. Zhang X, Lu XA, Yang J, Zhang G, Li J, Song L, et al. . Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with b-cell acute lymphoblastic leukemia with high-risk features. Blood Adv (2020) 4:2325–38. doi: 10.1182/bloodadvances.2020001466
    1. Chen YH, Zhang X, Cheng YF, Chen H, Mo XD, Yan CH, et al. . Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Cytotherapy (2020) 22:755–61. doi: 10.1016/j.jcyt.2020.08.002
    1. Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. . Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood (2017) 129:3322–31. doi: 10.1182/blood-2017-02-769208
    1. Ding L, Wang Y, Hong R, Zhao H, Zhou L, Wei G, et al. . Efficacy and safety of chimeric antigen receptor T cells in acute lymphoblastic leukemia with post-transplant relapse. Front Oncol (2021) 11:750218. doi: 10.3389/fonc.2021.750218
    1. Zhang X, Yang J, Li J, Li W, Song D, Lu XA, et al. . Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of b cell acute lymphoblastic leukemia. Cancer Immunol Immunother (2022) 71:689–703. doi: 10.1007/s00262-021-03009-z
    1. Hua J, Zhang J, Zhang X, Wu X, Zhou L, Bao X, et al. . Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent b-ALL after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant (2021) 56:1056–64. doi: 10.1038/s41409-020-01140-6
    1. Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, et al. . Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol (2021) 39:3978–92. doi: 10.1200/JCO.21.01992
    1. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. . Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood (2005) 106:2912–19. doi: 10.1182/blood-2005-05-2004
    1. Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. . International, multicenter standardization of acute graft-versus-host disease clinical data collection:a report from the mount Sinai acute GVHD international consortium. Biol Blood Marrow Transplant (2016) 22:4–10. doi: 10.1016/j.bbmt.2015.09.001
    1. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. . 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant (1995) 15:825–28.
    1. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. . Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood (2017) 129:424–47. doi: 10.1182/blood-2016-08-733196
    1. Jodele S, Dandoy CE, Myers KC, El-Bietar J, Nelson A, Wallace G, et al. . New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transfus Apher Sci (2016) 54:181–90. doi: 10.1016/j.transci.2016.04.007
    1. Liu P, Liu M, Lyu C, Lu W, Cui R, Wang J, et al. . Acute graft-versus-host disease after humanized anti-CD19-CAR T therapy in relapsed b-ALL patients after allogeneic hematopoietic stem cell transplant. Front Oncol (2020) 10:573822. doi: 10.3389/fonc.2020.573822
    1. Chen Y, Cheng Y, Suo P, Yan C, Wang Y, Chen Y, et al. . Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed b-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation. Br J Haematol (2017) 179:598–605. doi: 10.1111/bjh.14923
    1. Hua J, Zhang J, Wu X, Zhou L, Bao X, Han Y, et al. . Allogeneic donor-derived anti-CD19 CAR t cell is a promising therapy for Relapsed/Refractory b-ALL after allogeneic hematopoietic stem-cell transplantation. Clin Lymphoma Myeloma Leuk (2020) 20:610–16. doi: 10.1016/j.clml.2020.04.007
    1. Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH, et al. . Allogeneic t cells that express an anti-CD19 chimeric antigen receptor induce remissions of b-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-Versus-Host disease. J Clin Oncol (2016) 34:1112–21. doi: 10.1200/JCO.2015.64.5929
    1. Andreola G, Labopin M, Beelen D, Chevallier P, Tabrizi R, Bosi A, et al. . Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ≥10 years. Bone Marrow Transplant (2015) 50:1508–12. doi: 10.1038/bmt.2015.193
    1. Lu Y, Zhang JP, Zhao YL, Xiong M, Sun RJ, Cao XY, et al. . Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: a single center study. Front Immunol (2022) 13:1066748. doi: 10.3389/fimmu.2022.1066748
    1. Ruutu T, de Wreede LC, van Biezen A, Brand R, Mohty M, Dreger P, et al. . Second allogeneic transplantation for relapse of malignant disease:retrospective analysis of outcome and predictive factors by the EBMT. Bone Marrow Transplant (2015) 50:1542–50. doi: 10.1038/bmt.2015.186
    1. Yan CH, Liu QF, Wu DP, Zhang X, Xu LP, Zhang XH, et al. . Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease and graft-versus-host disease-guided multiple DLIs could improve outcomes after allogeneic hematopoietic stem cell transplantation in patients with refractory/relapsed acute leukemia. Biol Blood Marrow Transplant (2017) 23:1311–19. doi: 10.1016/j.bbmt.2017.04.028
    1. Zhao YL, Liu DY, Sun RJ, Zhang JP, Zhou JR, Wei ZJ, et al. . Integrating CAR T-cell therapy and transplantation:comparisons of safety and long-term efficacy of allogeneic hematopoietic stem cell transplantation after CAR T-cell or chemotherapy-based complete remission in b-cell acute lymphoblastic leukemia. Front Immunol (2021) 12:605766. doi: 10.3389/fimmu.2021.605766
    1. Chang YJ, Wang Y, Liu YR, Xu LP, Zhang XH, Chen H, et al. . Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry:a retrospective and prospective analysis. J Hematol Oncol (2017) 10:134. doi: 10.1186/s13045-017-0502-3
    1. Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, et al. . Haploidentical vs identical-sibling transplant for AML in remission:a multicenter, prospective study. Blood. (2015) 125:3956–62. doi: 10.1182/blood-2015-02-627786
    1. Imus PH, Blackford AL, Bettinotti M, Iglehart B, Dietrich A, Tucker N, et al. . Major histocompatibility mismatch and donor choice for second allogeneic bone marrow transplantation. Biol Blood Marrow Transplant (2017) 23:1887–94. doi: 10.1016/j.bbmt.2017.07.014
    1. Im A, Rashidi A, Wang T, Hemmer M, MacMillan ML, Pidala J, et al. . Risk factors for graft-versus-host disease in haploidentical hematopoietic cell transplantation using post-transplant cyclophosphamide. Biol Blood Marrow Transplant (2020) 26:1459–68. doi: 10.1016/j.bbmt.2020.05.001
    1. Yu J, Du Y, Ahmad S, Patel RD, Varela JC, Chang CC, et al. . Comparison of myeloablative versus reduced-intensity conditioning regimens in allogeneic stem cell transplantation recipients with acute myelogenous leukemia with measurable residual disease-negative disease at the time of transplantation:a retrospective cohort study. Transplant Cell Ther (2021) 27:661–63. doi: 10.1016/j.jtct.2021.04.017
    1. Shaw BE, Mufti GJ, Mackinnon S, Cavenagh JD, Pearce RM, Towlson KE, et al. . Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant (2008) 42:783–89. doi: 10.1038/bmt.2008.255
    1. Epperla N, Li A, Logan B, Fretham C, Chhabra S, Aljurf M, et al. . Incidence, risk factors for and outcomes of transplant-associated thrombotic microangiopathy. Br J Haematol (2020) 189:1171–81. doi: 10.1111/bjh.16457
    1. Dvorak CC, Higham C, Shimano KA. Transplant-associated thrombotic microangiopathy in pediatric hematopoietic cell transplant recipients:a practical approach to diagnosis and management. Front Pediatr (2019) 7:133. doi: 10.3389/fped.2019.00133
    1. Li A, Wu Q, Davis C, Kirtane KS, Pham PD, Sorror ML, et al. . Transplant-associated thrombotic microangiopathy is a multifactorial disease unresponsive to immunosuppressant withdrawal. Biol Blood Marrow Transplant (2019) 25:570–76. doi: 10.1016/j.bbmt.2018.10.015
    1. Wu MS, Koirala A. Thrombotic microangiopathy following chimeric antigen receptor T-cell therapy. Clin Nephrol Case Stud (2023) 11:17–21. doi: 10.5414/CNCS111045
    1. Oostenbrink L, Jol-van DZC, Kielsen K, Jansen-Hoogendijk AM, Ifversen M, Muller KG, et al. . Differential elimination of anti-thymocyte globulin of fresenius and genzyme impacts T-cell reconstitution after hematopoietic stem cell transplantation. Front Immunol (2019) 10:315. doi: 10.3389/fimmu.2019.00315
    1. Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation (1995) 59:1194–200.
    1. Chen X, Wei J, Huang Y, He Y, Yang D, Zhang R, et al. . Effect of antithymocyte globulin source on outcomes of HLA-matched sibling allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia. Biol Blood Marrow Transplant (2018) 24:86–90. doi: 10.1016/j.bbmt.2017.10.007
    1. Zhang Y, Liu L, Si Y, Miao M, Qiu H, Tang X, et al. . A comparative study of porcine antihuman lymphocyte globulin versus antithymocyte globulin-fresenius in an allogeneic hematopoietic cell transplantation conditioning regimen for severe aplastic anemia. Hematology (2021) 26:741–50. doi: 10.1080/16078454.2021.1974201
    1. Zhao J, Song Y, Liu D. Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia. J Hematol Oncol (2019) 12:17. doi: 10.1186/s13045-019-0705-x

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться